.

Dr Annalisa Jenkins appointed chair of the advisory board at RYSE Asset Management

We're thrilled to announce Dr Annalisa Jenkins will be chairing our advisory board in our mission to build a global digital future for healthcare!

Annalisa has been supporting us for many years and is a healthcare thought leader with a 25-year track record in building and leading teams from scientific research through clinical development, regulatory approval, and into healthcare systems globally.

She served as CEO of Dimension Therapeutics, a gene therapy company that was acquired by Ultragenyx Pharmaceutical Inc., is Chair of the Court at the London School of Hygiene and Tropical Medicine, U. of London, Trustee of the British Heart Foundation, Advisory Board member at MedCity, FasterCures, a Center of the Milken Institute, Genomics England, and member of the Science Advisory Board at the FDA.

Annalisa holds a degree in Medicine, specialised in Cardiovascular Medicine, served as a Medical Officer in the British Royal Navy, and prior leadership roles have included the head of global research and development at Merck Serono!

You can read the article on our LinkedIn page here.